Clinical Trial

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Study acronym: LITESPARK-033
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
Protocol Amendment History 5 changes
notable Trial sites expanded: 124 -> 127 locations 2026-08-04
notable Trial sites expanded: 119 -> 124 locations 2026-07-28
notable Trial sites expanded: 108 -> 111 locations 2026-06-13
notable Trial sites expanded: 105 -> 108 locations 2026-05-13
notable Trial sites expanded: 91 -> 100 locations 2026-04-14
Trial Details
NCT Number NCT07227402
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: Exelixis
Conditions Renal Cell Carcinoma
Enrollment 904 participants
Start Date 2025-11-26
Primary Completion 2032-02-27 (estimated)
Study Completion 2032-02-27 (estimated)
Updated on ClinicalTrials.gov 2026-08-03